BUZZ-Veradermics rises as oral hair-loss drug for women shows positive mid-stage data

** Shares of drug developer Veradermics MANE.N rise 15.8% to $127.59

** Stock on track for its biggest one-day gain for over two months if gains hold

** Co says its experimental oral hair-loss drug, VDPHL01, met the main goal in a mid-stage study in women with female pattern hair loss, a common condition that causes gradual hair thinning

** Says 89% of women on once-daily treatment and 90% on twice-daily treatment reported improved hair coverage after six months

** Patients grew about 23 additional hairs per square centimeter on average in the treated area, co says

** Citi analysts say visible hair growth by month two, similar efficacy across dosing regimens and no treatment-related serious or heart-related side effects strengthen the commercial case for VDPHL01 in female pattern hair loss

** Co expects data from an ongoing mid- to late-stage trial in women in H1 2027 and from a late-stage study in men in H2 2026

** Shares have risen ~12% since the co's February 4 IPO, based on last close